Transversus Abdominis Plane Block Versus Rectus Sheath Block After Cesarean Delivery
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03811067 |
|
Recruitment Status :
Completed
First Posted : January 22, 2019
Last Update Posted : July 23, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Postoperative Pain | Procedure: Transversus abdominis plane block Procedure: Rectus sheath block | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 90 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | Transversus Abdominis Plane Block Versus Rectus Sheath Block for Postoperative Pain After Cesarean Delivery: A Randomized Controlled Trial |
| Actual Study Start Date : | April 25, 2019 |
| Actual Primary Completion Date : | July 1, 2019 |
| Actual Study Completion Date : | July 15, 2019 |
| Arm | Intervention/treatment |
|---|---|
| No Intervention: Control group | |
|
Active Comparator: TAP group
Transversus abdominis plane block administered group
|
Procedure: Transversus abdominis plane block
Transversus abdominis plane block will be performed bilaterally after the surgery. |
|
Active Comparator: RS group
Rectus sheath block administered group
|
Procedure: Rectus sheath block
Rectus sheath block will be performed bilaterally after the surgery. |
- Morphine consumption [ Time Frame: Postoperative 24th hour. ]Morphine consumption (mg) of patients with patient controlled device
- NRS score [ Time Frame: Postoperative 24th hour ]Numerating rating scale of patients
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
ASA I-II patients Patients undergo elective cesarean delivery Gestation period between 37-40 weeks
Exclusion Criteria:
obesity (body mass index >35 kg/m2) infection of the skin at the site of needle puncture area patients with known allergies to any of the study drugs coagulopathy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03811067
| Turkey | |
| Kocaeli University | |
| Kocaeli, Turkey, 41350 | |
| Principal Investigator: | Hadi Ufuk MD Yörükoğlu | Kocaeli University |
| Responsible Party: | Hadi Ufuk Yörükoğlu, Principal investigator, Kocaeli University |
| ClinicalTrials.gov Identifier: | NCT03811067 |
| Other Study ID Numbers: |
KAEK 2017/348 |
| First Posted: | January 22, 2019 Key Record Dates |
| Last Update Posted: | July 23, 2019 |
| Last Verified: | July 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Postoperative pain Transversus abdominis plane block Rectus sheath block Cesarean delivery |
|
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Neurologic Manifestations |

